Clinical Trial Update: The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing MK-1293 to Lantus in adults with type 2 diabetes completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Lantus (insulin glargine)
• MK-1293 (insulin analogue? (MK-1293 is a follow-on insulin lispro-like agent))

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2017-03-08